General
Preferred name
TAK-285
Synonyms
Tak 285 ()
Tak285 ()
P&D ID
PD010574
CAS
871026-44-7
Tags
available
drug candidate
Drug indication
Solid tumour/cancer
Drug Status
investigational
Max Phase
1.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION TAK-285 is a novel dual erbB protein kinase inhibitor that specifically targets human epidermal growth factor receptor (EGFR) and HER2. Methods: TAK-285 is currently being developed by Takeda. TAK-285 was found to be well tolerate in Phase I trials. Absorption of TAK-285 was rapid after oral dosing, and plasma exposure at steady-state increased in a dose-proportional fashion for doses ranging from 50 to 300 mg b.i.d. A partial response was observed for one patient with parotid cancer who received 300 mg b.i.d. The toxicity profile and PK properties of oral TAK-285 warrant further evaluation. (BOC Sciences Bioactive Compounds)
Cell lines
1
Organisms
0
Compound Sets
13
AdooQ Bioactive Compound Library
A11236
BOC Sciences Bioactive Compounds
tak-285-cas-871026-44-7-item-84-460088
Cayman Chemical Bioactives
29157
ChEMBL Drugs
CHEMBL1614725
Clinical kinase drugs
Drug Repurposing Hub
DrugMAP
DM6KOBZ
EU-OPENSCREEN Bioactive Compound Library
EOS100402
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1614725
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
CHEMBL1614725
MedChem Express Bioactive Compound Library
HY-15196
ReFrame library
Selleckchem Bioactive Compound Library
tak-285
External IDs
23
Properties
(calculated by RDKit )
Molecular Weight
547.16
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
3
Rotatable Bonds
9
Ring Count
4
Aromatic Ring Count
4
cLogP
5.92
TPSA
101.3
Fraction CSP3
0.27
Chiral centers
0.0
Largest ring
6.0
QED
0.24
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Targets
ERBB2,EGFR
Target
ERBB2
EGFR
EGFR,HER2
MOA
EGFR inhibitor
Pathway
JAK/STAT Signaling
Protein Tyrosine Kinase/RTK
Source data